Passage Bio Inc (PASG) Stock Price, Quote & News

Company Profile

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metach...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 866 0311

Website: www.passagebio.com

Address:

One Commerce Square, 2005 Market Street 39th Floor, Philadelphia, United States

stu4 Jan. 7 at 5:44 PM

$PASG As Chardan…has completed its mission !!! Sold into you fools for 4 days ….and GONEEEEE

1 · Reply

RocketLynx Jan. 7 at 2:39 PM

$PASG The pre-cancer angle is the real alpha: advanced adenomas are harder than “already-cancer,” and they’ve cited 81–82% sensitivity for that lane while keeping CRC performance in the 90s (92/90 pooled, plus 94/97 in one interim set and 97/97 in another)

0 · Reply

stockmoe12 Jan. 7 at 3:33 AM

$PASG

0 · Reply

stockmoe12 Jan. 7 at 3:33 AM

$PASG without hype … its moving so lets go to $100

0 · Reply

BDE_Worldwide Jan. 7 at 2:45 AM

$PASG surprised no one is posting/hyping this one.. 🤔

1 · Reply

OvernightSwingKing Jan. 7 at 12:04 AM

$JCSE $MNTS $PASG $WDC Nice, a total of 3 good calls last year!!! BLOCKEDDDDDDDDD

0 · Reply

stockmoe12 Jan. 6 at 9:18 PM

$PASG buyout ????

1 · Reply

Trendrebel Jan. 6 at 5:17 PM

$PASG Still flying under radar...

0 · Reply

MaverikIT Jan. 6 at 4:46 PM

$CAPR $STOK $PASG @Jblack500 @WAJeff @cynicaloptimist @FannyPackin @Thelonius_Stonk @osubuckeye @Clargy

0 · Reply

www_larval_com Jan. 6 at 2:52 PM

Dumbo reporting in! $PASG just shot 10% higher to 16% (~87Kv) in the last few minutes, follow for more volatility.

0 · Reply

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Nov 5, 2025, 7:00 AM EST - 2 months ago

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Oct 14, 2025, 7:00 AM EDT - 3 months ago

Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference

Aug 28, 2025, 7:00 AM EDT - 4 months ago

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:00 AM EDT - 5 months ago

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Jul 10, 2025, 7:00 AM EDT - 6 months ago

Passage Bio Announces 1-for-20 Reverse Stock Split

Jun 23, 2025, 7:00 AM EDT - 7 months ago

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

May 13, 2025, 7:00 AM EDT - 8 months ago

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

Mar 4, 2025, 7:00 AM EST - 11 months ago

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Feb 26, 2025, 7:00 AM EST - 11 months ago

Passage Bio to Participate in Upcoming Investor Conferences

Jan 10, 2025, 7:00 AM EST - 1 year ago

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Nov 6, 2024, 7:00 AM EST - 1 year ago

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 10, 2024, 7:52 AM EDT - 1 year ago

Passage Bio Welcomes Tom Kassberg to Board of Directors

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 21, 2024, 8:00 AM EDT - 1 year ago

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

May 14, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 4, 2024, 7:00 AM EST - 2 years ago

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Feb 27, 2024, 7:00 AM EST - 2 years ago

Passage Bio to Participate in Upcoming Investor Conferences

Jan 31, 2024, 7:30 AM EST - 2 years ago

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 20, 2023, 7:00 AM EST - 2 years ago

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Nov 17, 2023, 4:30 PM EST - 2 years ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Nov 13, 2023, 7:00 AM EST - 2 years ago

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference

Oct 20, 2023, 4:30 PM EDT - 2 years ago

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines Conference

Aug 7, 2023, 7:15 AM EDT - 2 years ago

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

Jul 31, 2023, 7:00 AM EDT - 2 years ago

Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors

Jun 5, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 11, 2023, 7:00 AM EDT - 2 years ago

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

Apr 21, 2023, 4:01 PM EDT - 2 years ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 17, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

Mar 6, 2023, 1:07 PM EST - 3 years ago

Passage Bio, Inc. (PASG) Q4 2022 Earnings Call Transcript

Mar 6, 2023, 7:00 AM EST - 3 years ago

Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

Feb 28, 2023, 11:39 PM EST - 3 years ago

Passage Bio Undervalued On Price, Long-Term Gene Therapy Prospects

Feb 28, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Present at Cowen 43rd Annual Health Care Conference

Feb 27, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

Feb 24, 2023, 7:00 AM EST - 3 years ago

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Feb 15, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Dec 14, 2022, 7:00 AM EST - 3 years ago

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

Nov 10, 2022, 10:26 AM EST - 3 years ago

Passage Bio, Inc. (PASG) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 7:00 AM EST - 3 years ago

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

stu4 Jan. 7 at 5:44 PM

$PASG As Chardan…has completed its mission !!! Sold into you fools for 4 days ….and GONEEEEE

1 · Reply

RocketLynx Jan. 7 at 2:39 PM

0 · Reply

stockmoe12 Jan. 7 at 3:33 AM

$PASG

0 · Reply

stockmoe12 Jan. 7 at 3:33 AM

$PASG without hype … its moving so lets go to $100

0 · Reply

BDE_Worldwide Jan. 7 at 2:45 AM

$PASG surprised no one is posting/hyping this one.. 🤔

1 · Reply

OvernightSwingKing Jan. 7 at 12:04 AM

$JCSE $MNTS $PASG $WDC Nice, a total of 3 good calls last year!!! BLOCKEDDDDDDDDD

0 · Reply

stockmoe12 Jan. 6 at 9:18 PM

$PASG buyout ????

1 · Reply

Trendrebel Jan. 6 at 5:17 PM

$PASG Still flying under radar...

0 · Reply

MaverikIT Jan. 6 at 4:46 PM

$CAPR $STOK $PASG @Jblack500 @WAJeff @cynicaloptimist @FannyPackin @Thelonius_Stonk @osubuckeye @Clargy

0 · Reply

www_larval_com Jan. 6 at 2:52 PM

Dumbo reporting in! $PASG just shot 10% higher to 16% (~87Kv) in the last few minutes, follow for more volatility.

0 · Reply

blankstocker Jan. 6 at 2:51 PM

$PASG Wow. Something is going on with this price action.

0 · Reply

patb99 Jan. 6 at 2:51 PM

$PASG 🧐

0 · Reply

signaljumper Jan. 6 at 10:00 AM

$PASG Cash per shares 16.91 We still Trading under the cash of the companys. The value of the pipeline is not reflected in the current share price.

0 · Reply

topstockalerts Jan. 6 at 12:42 AM

Top Gainers PT2 $LHSW $DVLT $SOWG $INBS $PASG

0 · Reply

topstockalerts Jan. 5 at 9:45 PM

Top Gainers PT2 $LHSW $DVLT $SOWG $INBS $PASG

0 · Reply

Mart7810 Jan. 5 at 9:12 PM

$AQST I don't get it... -3%? $MIST -2% whit an approved FDA I'm in $PASG and +42% whit nothing today

1 · Reply

topstockalerts Jan. 5 at 7:49 PM

Top Gainers PT2 $VRME $LHSW $DVLT $MRNO $PASG

0 · Reply

Godwins26 Jan. 5 at 7:31 PM

Watchlist 😊 $TMDE $INBS $PASG $RGC $ASTI

0 · Reply

signaljumper Jan. 5 at 7:17 PM

$PASG Up over 63% since i call this Stock but i See another candle Up Follow for more runners Also Checkout my Investor blog at paetron https://www.patreon.com/signaljumper?utm_campaign=creatorshare_creator

0 · Reply

Godwins26 Jan. 5 at 6:39 PM

2nd Watchlist $TMDE $INBS $PASG $RGC $ASTI

0 · Reply

topstockalerts Jan. 5 at 6:12 PM

Top Gainers PT2 $JCSE $RGC $DVLT $PASG $AFJKU

0 · Reply

DiamondPlayz Jan. 5 at 6:11 PM

Seeing bulls rotate into PAVM now. Starting its massive run - Early positioning is key 💎 Low float tickers have been exploding 300% lately. Just 700k shares outstanding, don't miss PAVM ! $PAVS $KXIN $ANGH $PASG PASS

0 · Reply

Market Cap	37.16M
Revenue (ttm)	0.00
Net Income (ttm)	-64.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	100,700
Avg Vol	56,288
Day's Range	N/A - N/A
Shares Out	3.18M
Stochastic %K	88%
Beta	1.76
Analysts	Strong Sell
Price Target	$32.50